European countries are expected to face the most immediate and severe impact from the new U.S. tariffs on imported branded or patented pharmaceutical products, while India may remain less affected for now, according to a press release by the Global Trade Research Initiative (GTRI).
Chairperson of the topmost Pharmaceutical company, Pharmexcil, which earns 40 - 50 per cent of its total revenues from the American market also said, "Generic drugs are not impacted".
"India did not have good trade relations with Pakistan in any case. Pakistan denied India India Most Favoured Nation (MFN) status, and we imposed a 200 per cent tariff... So it's not great looking into the numbers in comparison to India's overall export of USD 800 billion," Sahai said.